BIO-ENGINEERED STENT MARKET ANALYSIS

Bio-engineered Stent Market, by Application Type (Coronary Artery Disease, Peripheral Arterial Disease, Carotid Artery Disease, Renal Artery Stenosis, Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Others), by Product Type (Drug-eluting Stents, Bioabsorbable Stents, and Drug-eluting Balloons), by Mode of Delivery (Balloon-expandable Stents and Self-expanding Stents), by Material Type (Metal-based and Polymer-based), by End User (Hospitals & Cardiac Centers and Ambulatory Surgical Centers, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Industry Insights and Forecast to 2026

Published In : Feb 2019
Code : CMI2484
Pages :176
Formats :
Excel and PDF
Industry : Medical Devices

Regional Analysis

Increasing adoption of bio-engineered stents in North America is expected to bolster the market growth

North America holds a dominant position in the global bio-engineered stent market, owing to rapid growth in geriatric population, increasing incidences of cardiac ailments, coronary and peripheral artery diseases, and high prevalence of obesity in the region. According to World Population Prospects, the number of people aged 80 or over is projected to triple by 2050, from 137 million in 2017 to 425 million in 2050 in the U.S. This age bracket is expected to more than double worldwide, increasing from 962 million in 2017 to 2.1 billion in 2050.

Moreover, key players in the market are focused on receiving regulatory approvals for novel products to reduce the burden of blood stream infections associated with bio-engineered stents. For instance, in September 2018, Biotronik SE & Co. KG received the U.S. Food and Drug Administration (FDA) approval for PK Papyrus covered coronary stent system for the treatment of acute coronary artery.

BIO-ENGINEERED STENT MARKET ANALYSIS

Regional Analysis

Bio-engineered Stent Market Report Snapshots

EXISTING CLIENTELE